4.6 Article

ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists

期刊

ATHEROSCLEROSIS
卷 209, 期 1, 页码 81-88

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2009.08.042

关键词

Acute phase response; Atherosclerosis; Endotoxin; Zymosan; Foam cell

资金

  1. Research Service of the Department of Veterans Affairs, National Institutes of Health [5R01HD029706]
  2. Albert L. and Janet A. Shultz Supporting Foundation

向作者/读者索取更多资源

Activation of macrophages by TLR agonists enhances foam cell formation, but the underlying mechanisms are not understood. We examined the effects of TLR agonists on ADRP/ADFP, a protein associated with forming lipid droplets, and Mal1 a fatty acid-binding protein, in two mouse macrophage cell lines and human monocytes. Low doses of LPS, a TLR4 agonist increased both mRNA and protein levels of ADRP/ADFP and Mal1 in RAW 264.7 macrophages. Following pretreatment with Intralipid, fatty acids, or acetyl-LDL to increase triglyceride or cholesterol ester storage, LPS treatment still increased ADRP/ADFP and Mal1 mRNA levels. LPS also induced ADRP/ADFP and Mal1 in J774 macrophages and ADRP/ADFP in human monocytes. Zymosan, a fungal product that activates TLR2, poly-I:C, a viral mimetic that activates TLR3, and imiquimod, a TLR7 agonist, also increased ADRP/ADFP. Zymosan, but not poly-I: C or imiquimod, induced Mal1. In contrast, neither gene was induced by TNF alpha, IL-1 beta, IL-6, or interferon-gamma. Thus TLR agonists induce ADRP/ADFP and Mal1, which likely contributes to macrophage triglyceride and cholesterol ester storage leading to foam cell formation. Published by Elsevier Ireland Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据